Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection.

IF 3.7 3区医学 Q2 ONCOLOGY

Cancer Epidemiology Biomarkers & Prevention Pub Date : 2024-12-19 DOI:10.1158/1055-9965.EPI-24-1096

Jing Li, Xiaobin Cao, Lulu Zhang, Aichen Liu, Siyu Liu, Fengqi Chen, Yutong Li, Hanke Ma, Wenke Sun, Songyun Ouyang, Liping Dai, Jingjing Liu

{"title":"Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection.","authors":"Jing Li, Xiaobin Cao, Lulu Zhang, Aichen Liu, Siyu Liu, Fengqi Chen, Yutong Li, Hanke Ma, Wenke Sun, Songyun Ouyang, Liping Dai, Jingjing Liu","doi":"10.1158/1055-9965.EPI-24-1096","DOIUrl":null,"url":null,"abstract":"Background: Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non-small cell lung cancer (NSCLC).Methods: A total of 1,155 plasma samples were divided into the verification and validation group. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using enzyme‑linked immunosorbent assay (ELISA). Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.Results: Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation group. The ELISA results were confirmed by western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an area under the curve (95% confidence interval, CI) of 0.806 (0.772-0.839) and 0.627 (0.584-0.670), respectively.Conclusions: Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.Impact: These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-24-1096","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis and affects the prognosis of lung cancer. In this study, we investigated whether the anti-FDX1 autoantibody could serve as a novel biomarker for the detection of non-small cell lung cancer (NSCLC).

Methods: A total of 1,155 plasma samples were divided into the verification and validation group. The expression levels of the anti-FDX1 autoantibody in 414 patients with NSCLC, 327 patients with benign pulmonary nodules (BPN), and 414 normal controls (NC) were detected using enzyme‑linked immunosorbent assay (ELISA). Western blotting and immunofluorescence analyses were performed to confirm the ELISA results.

Results: Plasma anti-FDX1 autoantibody levels were significantly higher in patients with NSCLC than in patients with BPN and NCs in the verification and validation group. The ELISA results were confirmed by western blotting and immunofluorescence. The anti-FDX1 autoantibody distinguished NSCLC from NC and BPN with an area under the curve (95% confidence interval, CI) of 0.806 (0.772-0.839) and 0.627 (0.584-0.670), respectively.

Conclusions: Our study demonstrated the potential benefits of the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.

Impact: These findings suggested that the anti-FDX1 autoantibody may facilitate the detection of NSCLC.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Epidemiology Biomarkers & Prevention 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.50

自引率

2.60%

发文量

538

审稿时长

1.6 months

期刊介绍： Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.